Corbus Pharmaceuticals

Historical price data

Corbus Pharmaceuticals is a clinical-stage biotech focused on developing innovative treatments for cancer and obesity, two of the most pressing global health challenges. Its strategy centers on optimizing known therapeutic modalities: a next-generation Nectin-4-targeting ADC (CRB-701) designed to improve upon first-generation toxicity, and a peripherally-restricted CB1 inverse agonist (CRB-913) aimed at achieving weight loss without central nervous system side effects. The company has advanced both lead assets into Phase 1 clinical trials, secured Fast Track designation for CRB-701 in specific cancers, and is positioning itself in multi-billion dollar markets with high unmet need.

Program-specific optimization of known modalities: next-generation ADC engineering with site-specific conjugation for oncology, and peripheral receptor targeting for metabolic disease.

CRB-701 directly challenges the entrenched Nectin-4 ADC PADCEV, requiring clear proof of superior tolerability. CRB-913 enters the fiercely competitive obesity market dominated by highly effective GLP-1s, needing to show compelling efficacy and a clean CNS safety profile to carve out a niche.